Alnylam CEO defends changes to crucial ATTR trial: ‘We really are playing to win’

NEW YORK — Al­ny­lam’s sur­prise change to the analy­sis plan for one of this year’s most an­tic­i­pat­ed clin­i­cal tri­al read­outs set off a flur­ry of ques­tions around the fu­ture of the com­pa­ny’s AT­TR fran­chise and the out­look of its up­com­ing re­sults.

“It’s not based on some, ‘Oh my good­ness, we’ve seen some­thing, there­fore we need to change,” Al­ny­lam CEO Yvonne Green­street said in an in­ter­view with End­points News in New York. In­stead, the up­dates could help Al­ny­lam show a greater dif­fer­ence be­tween the ef­fects of its med­i­cine and place­bo, and re­flect a com­mer­cial mar­ket that may re­sist pay­ing for Al­ny­lam’s ther­a­py in com­bi­na­tion with Pfiz­er’s drug tafamidis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.